Different modes of cell death regulate immunity. Whereas necrotic (necroptotic, pyroptotic) cell death triggers inflammation, apoptosis contributes to its resolution. Interleukin-1 (IL-1) family cytokines are key players in this interaction. A number of IL-1 family cytokines are produced by necrotic cells to induce sterile inflammation. However, release of IL-1 family proteins from apoptotic cells to regulate inflammation was not described. Here we show that IL-38, a poorly characterized IL-1 family cytokine, is produced selectively by human apoptotic cells to limit inflammation. Depletion of IL-38 in apoptotic cells provoked enhanced IL-6 and IL-8 levels and AP1 activation in co-cultured human primary macrophages, subsequently inducing Th17 cell expansion at the expense of IL-10-producing T cells. IL-38 was N-terminally processed in apoptotic cells to generate a mature cytokine with distinct properties. Both full-length and truncated IL-38 bound to X-linked interleukin-1 receptor accessory protein-like 1 (IL1RAPL1). However, whereas the IL-38 precursor induced an increase in IL-6 production by human macrophages, truncated IL-38 reduced IL-6 production by attenuating the JNK/AP1 pathway downstream of IL1RAPL1. In conclusion, we identified a mechanism of apoptotic cell-dependent immune regulation requiring IL-38 processing and secretion, which might be relevant in resolution of inflammation, autoimmunity, and cancer.
Introduction
The IL-1 family of cytokines and their receptors are a heterogeneous group of proteins that regulate immunity (Sims and Smith, 2010) . They exhibit a broad spectrum of functions in immunity, including the induction of Th1 and Th2 inflammation and provoking antiinflammatory or pro-resolving effects (Dinarello, 2009) . Triggering of inflammation is facilitated by IL-1 family cytokines with receptor agonist function , which is counteracted by IL-1 family receptor antagonists (IL-1Ra, IL-36Ra) (Dinarello, 2013) . With the exception of IL-1Ra, IL-1 family members are synthesized as precursors that require N-terminal processing to gain full receptor agonistic or antagonistic function (Towne et al., 2011) .
Different types of cell death regulate inflammation by modulating professional phagocyte activation. Controlled disintegration of cells, apoptosis, avoids an inflammatory response and actively contributes to resolving inflammation (Gregory and Pound, 2011) . In contrast, cell death involving cell lysis such as necrosis, necroptosis, and pyroptosis induces inflammation by release of pro-inflammatory molecules. Among these are IL-1 family receptor agonists, namely the precursors of IL-1a and IL-33, and the active form of IL-1b and IL-18, respectively (Vanden Berghe et al., 2014; Pasparakis and Vandenabeele, 2015) . An apoptosis-associated member of the IL-1 family, which would be expected to exhibit receptor antagonist function, has not been described. Our previous data suggested regulation of macrophage cytokine production by an IL-1 family protein in the context of macrophage -apoptotic cell interaction (Ley et al., 2013a) .
IL-1 family receptors possess an extracellular immunoglobulin domain and an intracellular TIR domain, which is necessary for signal transduction upon ligand binding. However, three orphan receptors, TIR8 (SIGIRR), TIGIRR-1 (IL1RAPL2), and TIGIRR-2 (IL1RAPL1), still exist within the IL-1 receptor family (Garlanda et al., 2013) , which exhibit a C-terminal 150-amino acid-long extension in their intracellular domain compared with other IL-1 family receptors. IL1RAPL1 is highly expressed in the brain and is involved in cerebellar development, mental retardation, and cognitive defects (Carrie et al., 1999; Born et al., 2000; Gambino et al., 2009) . Functional studies suggest that activation and downstream signaling of IL1RAPL1 differ from that of other IL-1 receptor family members, probably due to its structural differences (Born et al., 2000; Khan et al., 2004) . There is evidence that IL1RAPL1 selectively activates JNK (Khan et al., 2004; Pavlowsky et al., 2010) , which is involved in innate immune cell activation (Arthur and Ley, 2013) .
IL-38 (IL1F10) is the most recent addition to the IL-1 family (Bensen et al., 2001; Lin et al., 2001) . It shares 41% homology with IL-1Ra and 43% with IL-36Ra and was therefore proposed as an IL-1 receptor antagonist (Bensen et al., 2001) . Indeed, IL-38 can bind to IL1R6, reducing cytokine production after C. albicans stimulation or addition of IL-36 at low concentrations. Nevertheless, an increase in cytokine production was noted after LPS stimulation together with IL-38 (van de Veerdonk et al., 2012) . In general, IL-38 polymorphisms are associated with increased susceptibility for auto-inflammatory diseases such as spondyloarthritis, rheumatoid arthritis, and psoriatic arthritis (Chou et al., 2006; Rahman et al., 2006; Guo et al., 2010; Jung et al., 2010; Monnet et al., 2012) or with CRP levels (Dehghan et al., 2011) , suggesting a role of IL-38 in chronic inflammation. The present study demonstrates that N-terminally processed IL-38 is released from apoptotic cells to limit inflammatory macrophage and downstream Th17 activation by blocking IL1RAPL1 signaling.
Results

IL-38 is released from apoptotic cells to inhibit macrophage cytokine production
When investigating the production of a IL-1 family member from apoptotic cells, we detected markedly increased amounts of IL-38 in the supernatant of apoptotic (ACM) A549 lung or MDA-231 breast cancer cells compared with living (VCM) or necrotic (NCM) counterparts ( Figure 1A ). This was also observed for primary human neutrophils or PBMCs, although to a lesser extent ( Figure 1A) . The increased concentration of IL-38 in the supernatants correlated with increased IL-38 mRNA expression levels ( Figure 1B ) and IL-38 protein in the cell lysates ( Figure 1C ), suggesting the production of IL-38 during the apoptotic process rather than the release of Figure 1 IL-38 is secreted from apoptotic cells. (A-C) A549 human lung cancer cells, MDA-231 breast cancer cells, human primary PBMCs, and human primary neutrophils remained viable, were treated with TNF-a (20 ng/ml) and CHX (10 mM) (A549 and MDA-231) or Staurosporine (0.5 mg/ml) (PMBCs and neutrophils) to induce apoptosis, or were incubated at 608C for 30 min to induce necrosis. Respective supernatants and cell lysates of viable (VCM), apoptotic (ACM), or necrotic (NCM) cells were harvested and IL-38 levels were analyzed by ELISA (A, C) or by RT-PCR (B) . Data are mean + SEM of five independent experiments. (D) Secretion of IL-38 from apoptotic A549 cells was analyzed by ELISA at the indicated time points. Data are mean + SEM of five independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001. ANOVA with Bonferroni's correction.
Apoptotic cell-derived IL-38 limits inflammation | 427 a stored protein. Regarding the kinetics of IL-38 secretion, enhanced IL-38 cytokine levels were observed 12 h after apoptosis induction in A549 cell ACM ( Figure 1D) , coinciding with the occurrence of apoptosis markers. Moreover, increased IL-38 expression and release demanded cell death rather than signaling by the apoptotic stimuli per se. This became apparent when comparing cells treated with TNF-a alone, which do not undergo cell death and do not increase IL-38 expression and release, with cells treated with TNF-a and cycloheximide (CHX), which enter apoptosis and release IL-38 (Supplementary Figure S1) . Apoptotic cell-derived mediators modulate phagocyte responses, including cytokine production (Zitvogel et al., 2010) . We analyzed the role of IL-38 in the production of a panel of cytokines that are produced upon macrophage activation by LPS or upon their interaction with apoptotic cells (Ley et al., 2013b) . Of these, IL-6 and IL-8 production (Supplementary Figure S2) were regulated by IL-38. Addition of recombinant IL-38 to LPS-stimulated macrophages increased IL-6 and IL-8 production compared with LPS alone (Figure 2A ), confirming (1 ng/ml) alone or in combination with recombinant human IL-38 (IL-38aa1-152) at 10 ng/ml for 6 h. Cytokine production was measured using cytometric bead array and normalized results are shown. Data are mean + SEM of five independent experiments. (B) VCM and ACM were produced from control (Ctrl), IL-38 knockdown (shIL-38), or IL-38-overexpressing (oeIL-38) A549 cells. ELISA was performed to control knockdown and overexpression efficiencies. Data are mean + SEM of seven independent experiments. (C) The respective control (Ctrl), IL-38 knockdown (shIL-38), and IL-38 overexpression (oeIL-38) VCM and ACM were used to stimulate human macrophages for 24 h. Cytokine production was measured using cytometric bead array and normalized results are shown. Data are mean + SEM of five different experiments. (D) Human macrophages were transfected with an AP1 reporter construct and luciferase activity was measured after 24 h of stimulation with ACM from shCtrl and shIL-38 A549 cells. Background measurements obtained from mock-transfected cells were subtracted from each experimental value. Normalized results are shown. Data are mean + SEM of five independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001. ANOVA with Bonferroni's correction. previous observations (van de Veerdonk et al., 2012) . Since ACM already contained IL-38, we wondered whether endogenous IL-38 affected macrophage cytokine production. Therefore, IL-38 was overexpressed or knocked down in A549 cells before generating ACM ( Figure 2B) . Indeed, stimulation of human macrophages with ACM produced from IL-38-overexpressing A549 cells resulted in reduced secretion of IL-6 and IL-8, whereas stimulation with ACM of IL-38 knockdown A549 cells yielded higher IL-6 and IL-8 concentrations ( Figure 2C ). ACM itself did not contain significant levels of IL-6 or IL-8 (Supplementary Figure S2) . Among the prominent transcriptional regulators of cytokine production, which are regulated by the IL-1 family, are NFkB and AP1. As NFkB is blocked after macrophages interact with apoptotic cells (Weigert et al., 2007) , we asked whether IL-38 in ACM affected AP1 activation. Indeed, ACM of IL-38 knockdown A549 cellsinduced a more pronounced AP1 activation in macrophages carrying an AP1 luciferase reporter when compared with ACM of IL-38-producing cells ( Figure 2D ). In conclusion, endogenous IL-38 restricted inflammatory macrophage activation in response to apoptotic cells.
IL-38 antagonizes IL1RAPL1-dependent cytokine production in response to ACM
We hypothesized that IL-38 inhibits ACM-induced cytokine production by acting as a receptor antagonist. We analyzed two candidates of the IL-1 receptor family, IL1R6 and IL1RAPL1, for their association with IL-38. IL-38 binds to IL1R6 (van de Veerdonk et al., 2012) and IL1RAPL1 was required for ACM-induced cytokine production in macrophages (Ley et al., 2013a) . We first determined the mRNA level and cell surface expression of IL1R6 and IL1RAPL1 in macrophages after ACM or LPS stimulation ( Figure 3A-C) . IL1R6 expression in macrophages was low and was further downregulated at the mRNA level ( Figure 3A ) but not cell surface expression level ( Figure 3B and C) after ACM or LPS stimulation. In contrast, IL1RAPL1 expression was abundant and was further increased at both mRNA level ( Figure 3A) and cell surface expression level ( Figure 3B and C) at 6 h following LPS and at 6 and 24 h following ACM treatment. Moreover, IL1RAPL1 cell surface expression was reduced after 24 h LPS stimulation ( Figure 3B and C) . Next, we analyzed putative IL-38 binding to IL1RAPL1 by performing competition and receptor binding assays. For competition assays, human macrophages were incubated with recombinant human IL-38 before analyzing surface expression of IL1R6 or IL1RAPL1. No differences in IL1R6 cell surface expression were observed, probably due to its low abundance in macrophages. However, IL-38 competed with the IL1RAPL1 antibody used for FACS analysis ( Figure 3D and E), indicating that IL-38 may bind to IL1RAPL1. These results were validated in receptor binding assays using IL1R6-Fc or IL1RAPL1-Fc chimera-coated plates incubated with different IL-38 concentrations, as well as positive (IL-1b binding to IL1R1) and negative (IL-38 binding to BST2) controls. As expected, IL-38 bound to IL1R6 ( Figure 3E ). However, IL-38 also bound to IL1RAPL1 ( Figure 3F ). As these results suggested IL-38 to regulate cytokine production by binding to IL1RAPL1, we asked for the role of IL1RAPL1 versus IL1R6 in ACM-induced cytokine production. IL1R6 or IL1RAPL1 was knocked down in human macrophages (Supplementary Figure S3A ) and IL-6 and IL-8 levels were measured in supernatants after ACM stimulation. IL-6 and IL-8 production after ACM stimulation was IL1RAPL1-dependent ( Figure 4A ), whereas IL1R6 was not required ( Figure 4B ). The IL1RAPL1 knockdown-mediated reduction of cytokine production was also evident after stimulation with ACM lacking IL-38. When IL-38 was overexpressed in the ACM, the IL1RAPL1 knockdown-mediated cytokine reduction was abolished, probably due to IL-38 overabundance that blocks IL1RAPL1 signaling completely, leaving no further room for knockdown-dependent reduction ( Figure 4C ).
IL-38 regulates Th17 responses
Next, we asked for consequences of macrophage-dependent T cell activation. We isolated primary human T cells, stimulated them with antiCD3/antiCD28 beads and incubated them repeatedly for 7 days with supernatants of macrophages previously stimulated with ACM, ACM of IL-38 knockdown A549 cells, or ACM of IL-38-overexpressing cells and measured IL-10, IL-17, and IFN-g levels as well as cells T cell proliferation. Supernatants of macrophages stimulated with ACM reduced IFN-g and IL-10 production by T cells and slightly elevated IL-17 level ( Figure 5A and B). However, lack of IL-38 in ACM strongly elevated IL-17 production by T cells and further decreased IL-10 concentration ( Figure 5A ). Overexpression of IL-38 in ACM blocked IL-17 production from T cells, although it did not increase IL-10 expression ( Figure 5B ). T cell stimulation directly with ACM did not induce cytokine production, indicating that the IL-38-induced changes in T cell cytokine production are due to its effect on macrophage activation (Supplementary Figure S4) . ACM itself did not contain IL-10, IL-17, or IFN-g. These differences were independent of T cell proliferation, as ACM-triggered macrophage supernatants similarly reduced the number of T cell division, which might explain reduced IFN-g and IL-10 levels compared with that in control macrophage supernatants ( Figure 5C and D). These data show that IL-38 from apoptotic cells restricts macrophage-dependent generation of Th17 cells.
IL-38 is N-terminally processed
According to size and structure of the N-terminal pro-domain, IL-38 was assigned to the IL-36 subfamily (Garlanda et al., 2013; van de Veerdonk and Netea, 2013) , whose members possess a consensus motif predicting a N-terminal cleavage site (for IL-38 after aa19) (Towne et al., 2011) . In order to determine whether apoptosis induces IL-38 processing, C-terminally myc-tagged IL-38 was overexpressed in tumor cells and apoptosis was induced. After immunoprecipitating IL-38, SDS-PAGE gel electrophoresis was performed and two signals for IL-38 with an apparent mass difference of ,2 kDa were detected in western blots. The lower mass was more prevalent in apoptotic cells, suggesting IL-38 processing during apoptosis ( Figure 6A ). Interestingly, 2D electrophoretic separation did not reveal significant change in the isoelectric point of low-molecular weight versus high-molecular weight IL-38 ( Figure 6B and C). To identify the exact cleavage position in IL-38, proteins were stained with Coomassie blue and the IL-38-containing bands in the gel were analyzed by mass spectrometry (MS) ( Figure 6D , Supplementary Tables S1 and S2). ) or incubated with 50 ng/ml IL-38 for 15 min on ice before staining with polyclonal anti-IL1R6 or monoclonal anti-IL1RAPL1 and their respective PE-conjugated secondary antibodies. Representative flow cytometry histograms (D) and statistical quantification of median PE intensity (E) are displayed. Data are mean + SEM of five independent experiments. (F) Binding kinetics of IL-38 to immobilized IL1R6, IL1RAPL1, IL1R1, and BST2. 96-well plates were coated with 0.5 mg of human IL1R6, IL1RAPL1, IL1R1, and BST2 extracellular domain-Fc chimeras and incubated with increasing amounts of human recombinant IL-38 or IL-1b as indicated. IL-38 binding to the extracellular domain of the receptors was detected using biotinylated monoclonal IL-38 or biotinylated polyclonal IL-1b antibodies. Data are mean + SEM of five independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001. ANOVA with Bonferroni's correction.
Considering N-terminal acetylation as a very common posttranslational modification, three N-terminally acetylated peptides were identified, which all located very close to the N-terminus of IL-38 (position 2, 3, and 7), indicating post-translational processing ( Figure 6D ). Acetylation at the N-terminus of the peptide was observed by a completely shifted b-type ion series (sequencing Figure 4 The role of IL-1R6 and IL-1RAPL1 in cytokine production. Human macrophages were transfected with non-targeting siRNA (siCtrl) or siRNA directed against IL1RAPL1 (siIL1RAPL1) (A, C) or IL1R6 (siIL1R6) (B) and stimulated with VCM and ACM for 24 h (A, B) or with ACM (C) produced from control (Ctrl), IL-38 knockdown (shIL-38), or IL-38-overexpressing (oeIL-38) A549 cells. Cytokine production was measured using cytometric bead array and normalized results are shown. Data are mean + SEM of five independent experiments. **P , 0.01, ***P , 0.001. ANOVA with Bonferroni's correction.
Figure 5 IL-38 regulates the Th17 response. Human T cells were activated with anti-CD3/anti-CD28 beads, stained with a proliferation dye (eFluor 670), and stimulated with the supernatants of macrophages previously exposed to ACM from control A549 cells (ACM shCtrl/MF, ACM Ctrl/MF), IL-38 knockdown A549 cells (ACM shIL-38/MF), or IL-38-overexpressing cells (ACM oeIL-38/MF). After 7 days, cytokine production (A, B) and cell proliferation (C, D) was measured. (A and B) Cytokines were quantified using cytometric bead array and normalized results are shown. Data are mean + SEM of 10 independent experiments. T cell proliferation was determined by following eFluor 670 dilution. (C and D) Representative flow cytometry histograms are displayed. Data are mean + SEM of 10 independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001. ANOVA with Bonferroni's correction.
Apoptotic cell-derived IL-38 limits inflammation | from N-terminus to C-terminus of peptide fragments) including the b1-ion, which is not easy to observe in normal peptide spectra (Supplementary Figure S5) . The y-type ion series (sequencing from C-terminus to N-terminus of peptide fragments) was unmodified, which strongly supports the finding of the b-type ion series regarding N-terminal acetylation and indicates the generation of a 'true' acetylated N-terminus. Thus, our data suggest that IL-38 is indeed processed in apoptotic cells, although the predicted cleavage site was not confirmed.
Full-length and truncated IL-38 differently affect IL1RAPL1-dependent cytokine production IL-1 family cytokine processing alters biological activity. To determine differences in the activity of full-length and truncated IL-38, commercially available truncated IL-38, produced according to the predicted cleavage site (Towne et al., 2011) , was used. IL-6 and IL-8 concentrations in macrophage supernatants upon ACM stimulation alone or in combination with full-length (IL-38aa1-152) or truncated (IL-38aa20-152) IL-38 were determined. The truncated form of IL-38 induced a reduction in IL-6 and IL-8 production, recapitulating the function of the endogenous IL-38 in ACM. Interestingly, contrarily to what we observed after LPS stimulation, full-length IL-38 reduced IL-6 and IL-8 production as well ( Figure 7A ). This could be due to a processing of full-length IL-38 by proteases present in the ACM. IL-38 variants alone did not affect cytokine production ( Figure 7A ). To further analyze differences in the biological activity of both IL-38 forms, human macrophages were stimulated with IL-1b or LPS, alone or in combination with different concentrations of full-length (IL-38aa1-152) or truncated (IL-38aa20-152) IL-38. After IL-1b stimulation, high IL-38aa1-152 concentrations (20 and 10 ng/ml) significantly increased IL-6 production, whereas IL-38aa20-152 decreased IL-6 production even at low concentrations ( Figure 7B ). Interestingly, after LPS stimulation, only IL-38aa1-152 (20, 10, 5 ng/ml) affected IL-6 production ( Figure 7C ). Since IL-38 in ACM regulated IL-6 by interacting with IL1RAPL1, we determined if IL-38aa20-152 also bound to IL1RAPL1. Compared with the positive control (IL-1b binding to IL1R1), IL-38aa20-152 showed a stronger affinity to IL1RAPL1 as IL38aa1-152 (Figures 3Fand 7D) . Surprisingly, IL-38aa20-152 also displayed comparably strong affinity to IL1R1, which was not observed with IL-38aa1-152 (Figures 3Fand 7D) . Next, we asked whether the opposite roles of IL-38aa1-152 and IL-38aa20-152 in IL-6 production were both IL1RAPL1-dependent. Transient IL1RAPL1 knockdown was performed in macrophages and IL-6 concentrations in the supernatants were measured after stimulation with IL-1b alone or in combination with IL-38aa1-152 or IL-38aa20-152. As reported before in a different model (Pavlowsky et al., 2010) , the IL-1b response was IL1RAPL1-dependent. IL1RAPL1 knockdown in macrophages abrogated both IL-6 induction by full-length IL-38 and IL-6 suppression by truncated IL-38 ( Figure 7E ), indicating that IL-38 executes its Colored boxes show identified modifications on corresponding positions assigned by PEAKS7 software. Spectra were searched with mass tolerance for precursor of 10 ppm and for fragments of 0.05 Da. The false discovery rate for peptide identification was ,5%. Scores of supporting peptides of both apoptotic and viable cells are listed in Supplementary Tables S1 and S2. effects through this receptor.
IL-38 regulates the JNK/AP1 pathway downstream of IL1RAPL1
IL-38 regulated AP1 activation in macrophages upon interaction with apoptotic cells ( Figure 2D) . To analyze the signaling pathways that were affected by IL-38 downstream of IL1RAPL1, we first utilized HEK 293T cells co-transfected with an IL1RAPL1 overexpression construct (Supplementary Figure S3B) and an AP1 reporter construct. Cells transfected only with the reporter construct were used as controls. IL-1b was used previously as an IL1RAPL1-dependent JNK activator (Pavlowsky et al., 2010) , although it is unclear whether IL-1b is a low-affinity ligand for IL1RAPL1 or IL1RAPL1 positively modulates IL-1b signaling. IL-1b did not induce AP1 activation in control cells, but AP1 activation was observed when IL1RAPL1 was overexpressed. Interestingly, the mere presence of IL1RAPL1 was sufficient to increase AP1 activity in IL1RAPL1-overexpressing cells compared with control cells ( Figure 8A ). IL1RAPL1 therefore activated AP1 after IL-1b stimulation, but also upon overexpression without an exogenous ligand. To confirm this, HEK cells overexpressing IL1RAPL1 and IL-6 promoter constructs with or without point mutations in transcription factor-binding sites (AP1, NFkB, CREB, and CEBPb) were used (Xiao et al., 2004) . Overexpression of IL1RAPL1 activated the IL-6 promoter, which was abrogated when the AP1 and NFkB binding sites were mutated ( Figure 8B ). This suggested AP1 and NFkB activation at the IL-6 promoter downstream of IL1RAPL1 and the presence of an endogenous IL1RAPL1 ligand in HEK cells. Interestingly, even though after transfection there was an increase in the number of dead cells (Supplementary Figure S6) , there was no detectable IL-1a or IL-1b present in the system (data not shown). Next, we asked whether IL-38aa1-152 or IL-38aa20-152 affected AP1 activity downstream of IL1RAPL1. AP1 induction was negatively regulated by both IL-38 isoforms ( Figure 8C ). However, IL-38aa20-152 inhibited AP1 activity at lower concentrations compared with Figure 7 Full-length and truncated IL-38 have opposite roles in cytokine production and binding to IL1RAPL1. (A -C) Human macrophages were treated with ACM alone or in combination with recombinant human full-length (IL-38aa1-152) or cleaved (IL-38aa20-152) IL-38 (10 ng/ml) for 24 h (A) or with recombinant human IL-1b (50 ng/ml) (B) and LPS (1 ng/ml) (C) alone or in combination with different concentrations of recombinant human full-length (IL-38aa1-152) or cleaved (IL-38aa20-152) IL-38 for 6 h (B, C). IL-6 and IL-8 concentrations in the supernatants were measured using cytometric bead array and normalized results are shown. Data are mean + SEM of seven independent experiments. (D) Binding kinetics of cleaved IL-38 to immobilized IL1RAPL1. 96-well plates were coated with 0.5 mg of human IL1RAPL1, IL1R1, and BST2 extracellular domain-Fc chimeras and incubated with increasing amounts of human recombinant IL-38aa20-152 or human recombinant IL-1b as indicated. IL-38 binding to the extracellular domain of the receptor was detected using biotinylated monoclonal IL-38 or biotinylated polyclonal IL-1b antibodies. Data are mean + SEM of five independent experiments. (E) Human macrophages were transfected with non-targeting siRNA (siCtrl) or siRNA directed against IL1RAPL1 (siIL1RAPL1) and stimulated with recombinant human IL-1b (50 ng/ml) alone or in combination with different concentrations of recombinant human full-length (IL-38aa1-152) or cleaved (IL-38aa20-152) IL-38 for 6 h. IL-6 concentrations in the supernatants were measured using cytometric bead array and normalized results are shown. Data are mean + SEM of seven independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001. ANOVA with Bonferroni's correction.
Apoptotic cell-derived IL-38 limits inflammation | 433 IL-38aa1-152. Intracellular FACS analysis of phosphorylated JNK and p38 was performed to analyze IL-38-modulated signaling pathways mediating IL1RAPL-induced AP1 activity. After IL1RAPL1 overexpression, increased JNK but not p38 phosphorylation was observed, which was significantly reduced by IL-38aa20-152 but not IL-38aa1-152, confirming the potent inhibitory role of truncated (E and F) Human macrophages were transfected with an empty vector, AP1, NFkB, or IL-6 reporter construct. After transfection, macrophages were stimulated for 24 h with either IL-1b (50 ng/ml) (E) or ACM (F) alone or in combination with IL-38aa1-152 or IL-38aa20-152 (10 ng/ml). Luciferase activity was measured. Background measurements obtained from mock-transfected cells were subtracted from each experimental value. Normalized results are shown. Data are mean + SEM of seven independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001. ANOVA with Bonferroni's correction. Figure 8D ). Transferring these observations to the macrophage setting, we expressed AP1, NFkB, or IL-6 reporter construct in macrophages and stimulated with IL-1b alone or in combination with IL-38aa20-152 or IL-38aa1-152. IL-38aa20-152 decreased AP1 but not NFkB activity in macrophages, whereas IL-38aa1-152 was ineffective ( Figure 8E) . Thus, only truncated IL-38 suppressed AP1 activity in macrophages, consistent with the observations that AP1 activity was increased in macrophages stimulated with ACM lacking IL-38 ( Figure 2D ) and that truncated IL-38 reduced cytokine production after IL-1b treatment in an IL1RAPL1-dependent manner ( Figure 7B and E) . Along this line, when analyzing IL-6 promoter activity in macrophages expressing an IL-6 reporter construct, we observed that IL-1b-induced IL-6 promoter activity was reduced by IL-38aa20-152 but not by IL-38aa1-152 ( Figure 8E) . Thus, the IL-38aa1-152-mediated increase in IL-6 production ( Figure 7B ) was likely independent of transcriptional regulation. Finally, to analyze promoter activity regulation in the ACM context, we stimulated macrophages with ACM alone or in combination with both IL-38aa20-152 and IL-38aa1-152. Consistent with the results on cytokine production ( Figure 7A ), full-length and truncated IL-38 downregulated AP-1 and IL-6 promoter activity, whereas, as expected, ACM did not induce NFkB activity ( Figure 8F) . Stimulation of macrophages with IL-38 forms alone did not affect AP1, IL-6, or NFkB promoter activity (Supplementary Figure S7) .
IL-38 (
Discussion
IL-38 biology is largely unexplored. Nevertheless, the association of inflammatory pathologies with IL-38 polymorphisms (Chou et al., 2006; Rahman et al., 2006; Guo et al., 2010; Jung et al., 2010; Dehghan et al., 2011; Monnet et al., 2012) and structural similarities with IL-1Ra (Lin et al., 2001 ) suggested an immuno-regulatory role. Indeed, our data identify IL-38 as an apoptotic cell-released mediator that affects the phenotype of professional phagocytes. The particularly high IL-38 levels released from apoptotic tumor cells suggest a pro-tumor function by attenuating anti-tumor immune responses. However, increased IL-38 levels in apoptotic neutrophil supernatants allow a role during the resolution of inflammation. Both tumor immunity and resolution of inflammation depend on the Th17/Treg ratio. An imbalance (high Th17/Treg ration) of these two T cell populations has further been observed in autoimmune diseases (Eisenstein and Williams, 2009; Abdulahad et al., 2011) . In the present study, the Th17/Treg ratio, indicated by the signature cytokines IL-17/IL-10, was kept at a low level by apoptotic cell-derived IL-38. Since Th17 differentiation and expansion in humans requires the presence of IL-6 (Laurence and O'Shea, 2007) , altered IL-6 production in macrophages by IL-38 likely explains the effect on Th17 polarization. The low Th17/Treg ratio maintained by apoptotic cell-derived IL-38 is strikingly concordant with reports of increased susceptibility to auto-inflammatory conditions in patients with IL-38 gene polymorphisms (Chou et al., 2006; Rahman et al., 2006; Guo et al., 2010; Jung et al., 2010; Monnet et al., 2012) .
As other IL-1 family cytokines, IL-38 was N-terminally processed to gain the immunosuppressive activity that is typically assigned to apoptotic cells. However, our data do not support processing according to the consensus motif of the IL-36 subfamily to which IL-38 was assigned (Towne et al., 2011) . Processing according to this motif would occur after aa19 and result in a shift of the isoelectric point (pI ) from 4.6 (IL-38 precursor) to 4.45/4.39 (truncated IL-38), which we did not observe. Furthermore, mass spectrometry of the IL-38 variants revealed an alternative cleavage site at position 6, whose predicted pI of 4.6 corresponded with our 2D gel electrophoresis data. Our data for the first time suggest IL-38 processing by so far unknown factors activated and/or released during the apoptotic process. Further investigation is necessary to identify IL-38 proteases. IL-38 release from apoptotic but not necrotic cells suggests an active mechanism that, beside proteolysis, might involve IL-38 expression and a coordinated release mechanism. Accordingly, radiation-exposed mouse brains exhibited increased expression of pro-apoptotic factors but also IL-38 (Mehrotra et al., 2014) .
Our study suggests IL1RAPL1 as a receptor for IL-38. As shown recently (van de Veerdonk et al., 2012) , IL-38 binds to IL1R6, which is activated by IL-36 and inhibited by IL-36Ra (Debets et al., 2001; Towne et al., 2004) . IL1R6 was described to be expressed predominantly in human DCs (Mutamba et al., 2012) , corroborating our observation of low IL1R6 expression in macrophages. Instead, IL1RAPL1 was required for IL-6 production in macrophages after ACM stimulation. IL1RAPL1 is predominantly expressed in the brain. Nevertheless, there is evidence suggesting its relevance not only in brain physiology, but also in immunity and tumor biology (Chiyomaru et al., 2012; Galindo et al., 2012; Heinecke et al., 2014; Xu et al., 2014) . In our model, IL1RAPL1 was upregulated at the macrophage surface at 6 h after LPS stimulation, but downregulated after 24 h, the time point when regulatory mechanisms reduce the response to LPS. Upon ACM stimulation, an induction of IL1RAPL1 was apparent at 6 h as well as 24 h, indicating a lack of counter-regulatory mechanisms in this scenario.
It was previously reported that IL1RAPL1 activates JNK signaling, which was required for AP1 activation, but had no effect on NFkB activation (Born et al., 2000; Khan et al., 2004) . The notion that truncated IL-38 is an antagonist of IL1RAPL1 signaling is therefore supported by our findings that the amount of IL-38 in ACM was inversely proportional to AP1 activation in macrophages. IL1RAPL1 overexpression in HEK cells per se induced AP1 activation via JNK but not p38. This corroborates previous reports suggesting preferential JNK activation downstream of IL1RAPL1 (Khan et al., 2004; Pavlowsky et al., 2010) . Overexpression of IL1RAPL1 might induce AP1 activation in different ways. One explanation might be an increase in the basal activity of factors activating AP1. Another explanation would be the production of an endogenous ligand of IL1RAPL1. Signaling downstream of IL1RAPL1 increases IL-6 production as shown with an IL-6 reporter construct in IL1RAPL1-overexpressing HEK cells. As expected, IL-6 promoter activity in IL1RAPL1-expressing HEK cells was impaired when the AP1-binding site was mutated. Unexpectedly, this was also observed with the mutated NFkB-binding site, probably due to NFkB baseline activity. The JNK/AP1 pathway activated by IL1RAPL1 overexpression was antagonized by IL-38, and the truncated form showed superior activity in HEK cells and macrophages. Interestingly, the IL-38 precursor increased IL-6 production after IL-1b stimulation, which was also IL1RAPL1-dependent. However, IL-38 precursor induces neither AP1 activity in IL1RAPL1-overexpressing HEK cells nor AP1 or IL-6 promoter activity in macrophages. As mentioned above, IL1RAPL1 likely does not activate NFkB (Born et al., 2000; Khan et al., 2004) . We therefore hypothesize that full-length IL-38 enhances cytokine production by post-transcriptional mechanisms. Full-length IL-38 or the truncated form decreased IL-6 and IL-8 expression as well as IL-6 and AP1 promoter activity. As described for other members of this family (Afonina et al., 2015) , this could be explained by an extracellular processing of the IL-38 precursor by so far unknown proteases.
In summary, we show that apoptotic cells produce IL-38 and that IL-38 limits cytokine production in macrophages by antagonizing IL1RAPL1-dependent JNK phosphorylation and subsequent AP1 activation. As a consequence of altered macrophage cytokine production, IL-38 preserves a low Th17/Treg balance that is beneficial in autoimmunity, but may be detrimental during tumor development. Our study supports previous assumptions on the biological role of IL-38 as an IL-1 family receptor antagonist. The finding that more than one IL-1 family receptor are antagonized by IL-38, i.e. IL1R6 (van de Veerdonk et al., 2012) , IL1RAPL1, and presumably IL1R1, together with the association of IL-38 variants with arthritis, strongly suggests an important impact of IL-38 on limiting chronic inflammatory pathologies.
Materials and methods
Cell culture and reagents
A549 lung carcinoma cells, MDA-231 breast cancer cells, and HEK 293T embryonic kidney cells were maintained in DMEM supplemented with 5 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% heat-inactivated FCS (PAA Laboratories). A list of the reagents used can be found in Supplementary Materials and methods.
Generation of conditioned media
Generation of apoptotic cell-conditioned media (ACM) was performed as described previously (Weigert et al., 2006) . For details, see Supplementary Materials and methods.
Primary cell isolation and differentiation
Human macrophages, neutrophils, and T cells were generated from buffy coats of anonymous healthy donors (DRK-Blutspendedienst Baden-Württemberg-Hessen, Institut für Transfusionsmedizin und Immunhämatologie Frankfurt am Main, Frankfurt, Germany) using Ficoll-Hypaque gradients. For details, see Supplementary Materials and methods.
T cell polarization assay
T cells were incubated with CD3/CD28 Dynabeads (Invitrogen) for 30 min at 378C, labeled with 5 mM cell proliferation dye eFluor670 (eBioscience), washed and incubated in T cell medium (RPMI supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 10% heat-inactivated FCS, 1% MEM not essential amino acids, 1% sodium pyruvate, and 1% HEPES buffer solution, PAA Laboratories) for 7 days. For T cell stimulation, supernatants of macrophages previously stimulated with ACM from control, IL-38 knockdown A549 cells, or IL-38-overexpressing cells, or ACM itself were used. Macrophage supernatants were diluted 1:2 in T cell medium before stimulation. T cell proliferation was determined by following eFluor670 dilution. IFNg, IL-10, and IL-17 concentrations were measured in the supernatant of T cells on Day 7.
IL-38 ELISA
IL-38 was measured using a direct ELISA. 96-well high-binding ELISA plates (Greiner bio-one) were coated with cell supernatants or recombinant human IL-38 overnight at 48C. After blocking with 2% PBS-BSA, anti-human IL-38 antibody was added to the wells followed by a biotinylated secondary antibody, HRP-conjugated streptavidin (R&D), and its substrate (R&D). The detection limit was 2 ng/ml and 50 pg/ml for the full-length and truncated IL-38, respectively. No cross-reactivity was observed with other members of the IL-1 family (Supplementary Figure S8) .
Receptor binding assay
96-well high-binding plates were coated overnight at 48C with 0.5 mg of recombinant human IL1R6/Fc chimera (R&D Systems), recombinant human IL1R1/Fc chimera (Sino Biological Inc.), recombinant human BST2/Fc chimera (Sino Biological Inc.), or recombinant human IL1RAPL1/Fc chimera (Sino Biological Inc.) in PBS. After blocking with 10% FCS, increasing concentrations of recombinant human IL-1b, IL-38aa1-152, or IL-38aa20-152 (in 2% FCS) were added to the wells and incubated overnight at 48C. Bound IL-38 was detected using a biotinylated anti-IL-38 or biotinylated anti-IL1b (R&D Systems) followed by the HRP-conjugated streptavidin and its substrate.
Receptor surface expression and binding competition assay
Receptor expression on the surface of human macrophages was determined using flow cytometry. Cells were detached and blocked for 15 min on ice with 0.5% PBS-BSA containing Fc-blocking reagent (Miltenyi Biotec). Afterwards, cells were incubated with anti-human IL1R6, anti-human IL1RAPL1, or the corresponding isotype control (R&D) for 30 min on ice. Phycoerythrin-conjugated secondary antibodies were added (Life technologies), and cells were analyzed with the LSR Fortessa flow cytometer (BD Biosciences). For competition assays, recombinant human IL-38 was incubated together with the Fc-blocking reagent.
RNA extraction and quantitative real-time PCR
RNA was extracted using pegGOLDRNAPure (Peqlab Biotechnologie). For reverse transcription of 1 mg mRNA, the iScript TM cDNA Synthesis Kit (Bio-Rad) was used. Quantitative real-time PCR was performed with the MyiQiCycler system (Bio-Rad) and Absolute QPCR SYBR Green Mix (ABgene). Relative mRNA expression was calculated with the Bio-Rad GeneEx gene expression macro, based on the ddC t method and normalized to 18S ribosomal RNA. A list of primers is available in Supplementary Materials and methods.
Cytokine quantification
IL-6, IL-8, IL-10, IL-17, and IFNg protein concentrations in cell supernatants were measured by FACS using Cytometric Bead Array Flex Sets (BD Biosciences). Samples were acquired with the LSR Fortessa flow cytometer (BD Biosciences) and analyzed with BD Biosciences FCAP software (V1.0.1).
Cell transfection
Human macrophages were transfected with siRNA against IL1R6 (Qiagen) or IL1RAPL1 (Thermo Scientific) using Hiperfect according to the manufactureŕs protocol. A549 cells were transfected with a Myc-tagged IL-38 expression plasmid (Origene) using the Nano Juice transfection reagent (Merck). For IL-38 knockdown, A459 cells were transduced with shRNA against IL-38 (Sigma-Aldrich) using lentiviral vectors. shControl cells were transfected with a lentiviral vector encoding non-targeting shRNA.
Isolation, detection, and identification of Myc-tagged IL-38
Myc-tagged IL-38 was expressed in A549 cells followed by induction of apoptosis as described above. After harvest, Myc-tagged IL-38 was enriched using the mMACS c-myc isolation kit (Miltenyi Biotec). Protein eluates were separated using 1D or 2D gel for IL-38 detection, or used for IL-38 identification by mass spectrometry. For details, see Supplementary Materials and methods.
Luciferase reporter assays
HEK 293T cells were transiently co-transfected with 2 mg of HA-tagged IL1RAPL1 expression plasmid (kindly provided by Prof. Dr Carlo Sala, University of Milan, Italy) (Pavlowsky et al., 2010) or an empty vector, together with 2 mg of AP1 luciferase reporter construct, a pGL3 control plasmid or different IL-6 reporter constructs with or without point mutations in binding sites for AP1, NFkB, CREB, and CEBPb (kindly provided by Dr Farrar, National Institute of Health, USA) (Xiao et al., 2004) , and 0.2 mg of Renilla luciferase control vector pRL-TK (Promega) using jetPEI transfection reagent (Polyplus transfection). After 24 h, growth medium was replaced and IL-1b, IL-38aa1-152, or IL-38aa20-152 was added for another 24 h. Human macrophages were transfected with 2 mg of AP1, NFkB, IL-6, or pGL3 control luciferase reporter construct and 0.2 mg of Renilla luciferase control vector pRL-TK (Promega) using jetPEI-Macrophage (Polyplus transfection). After 24 h, macrophages were stimulated with IL-1b alone or in combination with IL-38aa1-152 or IL-38aa20-152 for 24 h and luciferase activities in cell lysates were measured. Firefly luciferase activity was normalized to Renilla luciferase activity in the lysate. For the IL1RAPL1-overexpressing HEK cells, the activity was expressed as fold induction compared with the cells transfected with an empty vector. The background obtained from mock-transfected cells was subtracted from each experimental value.
Intracellular staining of phosphorylated proteins
For measurement of phospho-JNK and phospho-p38, HEK 293T cells were transfected with 2 mg of HA-tagged IL1RAPL1 expression plasmid using jetPEI transfection reagent (Polyplus transfection). Forty-eight hours after transfection, cells were stimulated with IL-38aa1-152 or IL-38aa20-152 for 10 min. Cells were fixed with 4% formaldehyde for 10 min at 378C and permeabilized with 90% methanol for 30 min on ice. Afterwards, cells were blocked for 15 min on ice using 0.5% PBS-BSA with Fc-Blocking reagent, followed by addition of phospho-JNK and phospho-p38 antibodies. After washing, secondary antibodies were added and cells were analyzed using the LSR Fortessa flow cytometer.
Supplementary material
Supplementary material is available at Journal of Molecular Cell Biology online.
